ARE Stock Analysis: Alexandria Real Estate | NYSE
REIT - Office | NYSE, USA | Market Cap: 8.321m USD | 12M Return: -29% | US0152711091 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 87.1M
Qual. Beats: 0
Rev. Trend: 46.4%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Alexandria Real Estate Equities (ARE) is an S&P 500 mission-driven life science REIT and a pioneer of the life science real estate niche. The company owns, operates, and develops large-scale Megacampus ecosystems clustered in top-tier innovation hubs, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. Headquartered in Pasadena, California, Alexandria was established on January 5, 1994, and is incorporated in Maryland.
As a REIT in the Diversified REITs sub-industry, Alexandria is structured to benefit from U.S. tax rules that require it to distribute the majority of its taxable income to shareholders as dividends. Its core business model focuses on providing highly specialized laboratory and research facilities tailored to pharmaceutical, biotechnology, and medical device tenants, a niche distinct from traditional office or residential REITs.
- Biotech funding recovery drives life science lab space demand
- Interest rate cuts pressure REIT cap rates and valuation
- Megacampus development pipeline expands future rental revenue
| Net Income: -904.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -1.24 > 1.0 |
| NWC/Revenue: -139.6% < 20% (prev -69.07%; Δ -70.55% < -1%) |
| CFO/TA 0.04 > 3% & CFO 1.28b > Net Income -904.0m |
| Net Debt (12.7b) to EBITDA (425.6m): 29.83 < 3 |
| Current Ratio: 0.11 > 1.5 & < 3 |
| Outstanding Shares: last quarter (188.4m) vs 12m ago 10.72% < -2% |
| Gross Margin: 69.46% > 18% (prev 69.38%; Δ 0.08% > 0.5%) |
| Asset Turnover: 8.19% > 50% (prev 8.03%; Δ 0.16% > 0%) |
| Interest Coverage Ratio: -3.39 > 6 (EBIT TTM -846.5m / Interest Expense TTM 249.5m) |
| DSRI: 0.10 (Receivables 7.66m/283.3m, Revenue 2.96b/3.02b) |
| GMI: 1.00 (GM 69.38% / 69.46%) |
| AQI: 0.12 (AQ_t 0.12 / AQ_t-1 0.95) |
| SGI: 0.98 (Revenue 2.96b / 3.02b) |
| TATA: -0.06 (NI -904.0m - CFO 1.28b) / TA 34.6b) |
| Beneish M = -4.31 (Cap -4..+1) = AAA |
As of August 12, 2026, the stock is trading at USD 48.12 with a total of 955,191 shares traded. Over the past week, the price has changed by -1.53%, over one month by +0.08%, over three months by +5.98% and over the past year by -28.96%.
Current recommended Stop Loss: 43.50 (which is 9.6% or 2.2 ATR below the current price).
Alexandria Real Estate has received a consensus analysts rating of 3.54. Therefore, it is recommended to hold ARE.
- StrongBuy: 3
- Buy: 1
- Hold: 9
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 52.4 | 8.8% |
P/E Forward = 16.6945
P/S = 2.9295
P/B = 0.5503
P/EG = 3.2356
Revenue TTM = 2.96b USD
EBIT TTM = -846.5m USD
EBITDA TTM = 425.6m USD
Long Term Debt = 10.8b USD (from longTermDebt, last quarter)
Short Term Debt = 1.99b USD (from shortTermDebt, last quarter)
Debt = 13.2b USD (from shortLongTermDebtTotal, last quarter) + Leases 354.9m
Net Debt = 12.7b USD (calculated: Debt 13.2b - CCE 470.4m)
Enterprise Value = 21.0b USD (8.32b + Debt 13.2b - CCE 470.4m)
Interest Coverage Ratio = -3.39 (Ebit TTM -846.5m / Interest Expense TTM 249.5m)
EV/FCF = 23.99x (Enterprise Value 21.0b / FCF TTM 876.1m)
FCF Yield = 4.17% (FCF TTM 876.1m / Enterprise Value 21.0b)
FCF Margin = 29.63% (FCF TTM 876.1m / Revenue TTM 2.96b)
Net Margin = -30.57% (Net Income TTM -904.0m / Revenue TTM 2.96b)
Gross Margin = 69.46% ((Revenue TTM 2.96b - Cost of Revenue TTM 903.3m) / Revenue TTM)
Gross Margin QoQ = 73.95% (prev 66.60%)
Tobins Q-Ratio = 0.61 (Enterprise Value 21.0b / Total Assets 34.6b)
Interest Expense / Debt = 1.89% (Interest Expense 249.5m / Debt 13.2b)
Taxrate = 16.39% (9.03m / 55.1m)
NOPAT = -707.8m (EBIT -846.5m * (1 - 16.39%)) [loss with tax shield]
Current Ratio = 0.11 (Total Current Assets 510.1m / Total Current Liabilities 4.64b)
Debt / Equity = 0.85 (Debt 13.2b / totalStockholderEquity, last quarter 15.6b)
Debt / EBITDA = 29.83 (Net Debt 12.7b / EBITDA 425.6m)
Debt / FCF = 14.49 (Net Debt 12.7b / FCF TTM 876.1m)
Total Stockholder Equity = 15.8b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.50% (Net Income -904.0m / Total Assets 34.6b)
RoE = -5.70% (Net Income TTM -904.0m / Total Stockholder Equity 15.8b)
RoCE = -3.17% (EBIT -846.5m / Capital Employed (Equity 15.8b + L.T.Debt 10.8b))
RoIC = -2.22% (negative operating profit) (NOPAT -707.8m / Invested Capital 31.8b)
WACC = 3.82% (E(8.32b)/V(21.5b) * Re(7.37%) + D(13.2b)/V(21.5b) * Rd(1.89%) * (1-Tc(0.16)))
Discount Rate = 7.37% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 62.27 | Cagr: 4.14%
[DCF] Terminal Value 73.10% ; FCFF base≈1.09b ; Y1≈959.0m ; Y5≈774.8m
[DCF] Fair Price = N/A (negative equity: EV 12.4b - Net Debt 12.7b = -260.3m; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.03 | # QB: 0
Revenue Correlation: 46.37 | Revenue CAGR: 1.52% | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.00 | Chg30d=+100.00% | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=1.80 | Chg30d=-2.89% | Revisions=+25% | GrowthEPS=+121.3% | GrowthRev=-13.2%
EPS next Year (2027-12-31): EPS=-0.81 | Chg30d=+7.95% | Revisions=+0% | GrowthEPS=-134.7% | GrowthRev=-5.5%
[Analyst] Revisions Ratio: +25% (up=1, down=0)